Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome


https://doi.org/10.4081/dr.2011.e55
Vol. 3 No. 3 (2011)
Submitted: 11 October 2011
Accepted: 9 November 2011
Published: 1 December 2011
Basal cell carcinoma, vismodegib, basal cell nevus syndrome, hedgehog
Abstract Views: 1609
PDF: 733
HTML: 68
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Glen J. Weiss
    gweiss@tgen.org
    Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Raoul Tibes Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Lisa Blaydorn Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Gayle Jameson Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Molly Downhour Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Erica White Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
  • Ivor Caro Genentech, South San Francisco, CA, United States.
  • Daniel D. Von Hoff Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, AZ, United States.
Tumor responses in advanced basal cell carcinoma (BCC) have been observed in clinical trials with vismodegib, a SMO antagonist. The result of SMO antagonism is inhibition Hedgehog Signaling Pathway (HHSP) downstream target genes. HHSP inhibition has been shown to affect stem cells responsible for blood, mammary, and neural development. We report on our experience of treating two patients with advanced BCC participating. These two patients have had no new BCCs develop for at least 2.25 years. Both patients have been receiving ongoing daily treatment with vismodegib for greater than 2.75 years without experiencing any significant side effects. After prolonged continuous daily dosing with a SMO antagonist, we have not observed a significant alteration in hematologic parameters or physical abnormalities of the pectoral regions of two patients with advanced BCC.

Supporting Agencies

This study was supported in part by Genentech. Disclosures, Genentech provided funding for the clinical trial involving vismodegib.

Weiss, G. J., Tibes, R., Blaydorn, L., Jameson, G., Downhour, M., White, E., Caro, I., & Von Hoff, D. D. (2011). Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome. Dermatology Reports, 3(3), e55. https://doi.org/10.4081/dr.2011.e55

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC